Biosensor Based Advanced Cancer Diagnostics and Therapy

Dear Colleagues,

Cancers are still a major cause of death because of limited success in therapy. The major obstacles are the lack of specific and reliable biomarkers to sense their emergence at the early stage, heterogeneous nature in terms of histology and morphology, as well as genomic variation and phenotypic manifestation, and specific targets for designing an efficacious means of individual therapy. Organ-specific sensors are rarely found, and even when they are found, they are not useful for predicting malignant potential, for example, PSA (prostate-specific antigen), and thus, they are not as commonly used as sensors for advanced cancer diagnostics and therapy. By contrast, tumor-associate antigens are commonly used for the same purposes. In the past decade, progressive development of better-affinity aptamers, antibodies, and engineered antibodies to disease biomarkers has been achieved, with concurrent advances in nanotechnology, which has stimulated and increased the development of nanomaterials-based biosensors to gradually replace the classical diagnostic methods and therapeutic means. In this issue, biomarkers/biosensors (e.g., signaling molecule, cell adhesion molecules, telomerase, tumor suppressors, microRNA, immune checkpoint, circular tumor marker DNA, tumor spheroid, tumor-related exosomes), as well as different types of transducers (e.g., electrochemical, optical, thermal, and piezoelectric) are used to fulfill the above needs. Therapeutic approaches, such as anticancer drug therapy, chem-photothermal therapy, and immune checkpoint therapy, are also included to meet the needs in the field.

Original research articles are preferred for this issue.

Prof. Dr. Guang-Jer Wu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sensors is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• signaling molecule
• METCAM
• microRNA
• circular tumor marker DNA
• tumor-related exosome
• telomerase
• tumor suppressor
• tumor spheroid
• LFIS
• anticancer drug
• chem-photothermal therapy
• immune checkpoint therapy